Frequently Asked Questions
Greyhounds Australasia (GA) Proposed Rule Changes (March 1 2018)

Q: Do the proposed rules apply to me from 1 March 2018?
A: The rules issued by GA, known as national rules, do not have any effect in each State until they are approved by the Controlling Body. Controlling Bodies will undertake their own consultation processes on the proposed rule changes and, subject to consideration of that feedback, consider whether or not they should be introduced in their State.

Q: How can I give feedback on the proposed GA Rules before they are considered by the Controlling Bodies?
A: Check with your own Controlling body how to make submissions on the proposed amendments.

Specific questions seeking clarification about any of the proposed rule changes or their meaning should be emailed to Greyhounds Australasia admin@galtd.org.au.

Q: Why should the definition of “prohibited substance” be changed?
A: The basic underlying principle is that we should have “drug-free racing” so that punters can be confident that greyhounds run on their merits and their performance is not influenced in any way by any sort of drug or other substance. This means that when they are presented to race, greyhounds must not have anything falling within the definition of prohibited substances in their system (as defined in GAR 1). The definition essentially includes any substance that can have an effect on any body system in the greyhound. Many of these compounds can be used in the routine practice of training greyhounds, they just need to be out of the dog’s system on raceday.

Regulatory bodies are not, and have never been, concerned with applying the rule unreasonably so as to capture the provision of food (or the vitamins/electrolytes that are present in normal foodstuffs) and water. To do so is clearly not in the interests of the sport or the regulation of it.

There has at times been confusion as to whether a substance was prohibited because it may not have been an example listed within the drug classes. This is particularly the case if the substance category/class is not listed in the rule, but was administered with the intent of having an effect on one of the body systems mentioned in the racing rules, or the substance is listed within the Commonwealth Poisons Standard, and therefore met the definition of prohibited substance within the rules.

The definition of prohibited substance has not been updated in over 20 years. Upon review of the rule, as conducted by GA’s Vets and Analysts Committee, it was proposed to amend the rule from an out-dated, inconsistent short definition to a more specific list of those substances that are prohibited in order to provide more clarity to participants.

The proposed lists of mammalian body systems and drug categories are identical to those used in horse racing under AR178B of the Australian Rules of Racing, which uses the same drug testing laboratories as the greyhound racing Controlling Bodies. All of the categories listed in the proposed rule are considered to already be an example of a prohibited substance under the current definition.
Q: What’s the difference between prohibited substance and banned substance?
A: There is group of prohibited substances that are so concerning from a welfare or integrity point of view that they are deemed to have no place in the sport at all – these are called permanently banned prohibited substances. It is these substances that not only cannot be in the greyhound’s system on raceday but also cannot be present in an out-of-competition sample. Because these substances are so concerning for the integrity of the sport, participants are also not permitted to possess, acquire, attempt to acquire, administer or attempt to administer any of these substances at any time from birth to retirement of a greyhound (GAR 79A).

So, all permanently banned prohibited substances are also prohibited substances but not all (in fact relatively very few) prohibited substances are permanently banned prohibited substances.

Q: The list of prohibited substances includes things like vitamins – does that mean I can’t give vitamins to my racing greyhound?
A: Most substances that might already be administered by injection already meet the current definition of a prohibited substance as they are being administered to cause some effect on a body system. If that were not the intention, then would be no purpose for administering the substance.

However, many of these injections may contain substances not readily detectable by a laboratory or that are indistinguishable from naturally occurring substances. In those that occur naturally, specific research would need to be done to prove that a substance has been administered too close to racing and a threshold developed, as was done with cobalt.

The list of prohibited substances in Part B therefore only refers to vitamins that can administered by injection if required, but which cannot be injected within one clear day of racing (see clarification below in relation to treatment prior to racing).

Q: Why should the definition of “exempted substance” be changed?
A: The definition of exempted substance is proposed to be amended to add norethisterone (when administered in the prescribed way) as a treatment for the purpose of regulating or preventing oestrus in female greyhounds. Owners and trainers in consultation with their prescribing veterinarian will now have more flexibility in choosing the best form of oestrus control treatment (if any) for that greyhound, instead of the only current option of ethyloestrenol, which many have reported does not suit all females.

Norethisterone is readily available as a human pharmaceutical and is currently used in racing greyhounds in the United Kingdom and New Zealand.

Q: Why should the restrictions on treatment prior to racing be changed?
A: The current definition of “race day treatment” has been identified as causing confusion with some participants.

The proposed change is intended to make it clear that no treatment can be given to a greyhound on the day the greyhound is nominated to compete in an Event. That is, no ‘treatment’ can be administered on the calendar day of racing, from 12:01am until the dog is removed from the racecourse after the completion of that Event with the permission of the Stewards pursuant to Rule 42(2), or is scratched with the permission of the Stewards.

This position is already in place for other racing codes and as is the case in the other codes, these rules focus on what is considered an acceptable practice on raceday (rather than on the substance itself – which is the ambit of raceday sampling and subsequent analysis).
Q: My State already has a rule that doesn’t allow me to race a greyhound in races over consecutive days. Why is the rule being proposed?

A: Western Australia, Tasmania, South Australia and Victoria already have this as part of their Local Rules. If adopted, this rule will harmonise the national rules and establish a national standard.

Q: Why should requirements about treatment records be changed?

A: The rule change proposed is intended to ensure that participants keep timely and accurate records of treatments administered to greyhounds. When treatment records are not kept on the day the treatment is given, they can be forgotten about or recorded inaccurately.

While most participants already adopt an approach which records treatments as soon as they are given, there are instances where these records are not available when requested by an authorised person or steward.
Change to definition of prohibited substances to be made in Greyhounds Australasia Rules

Notice to trainers – The definition of prohibited substance within GAR 1 is to be updated

On 1 March 2018, Greyhounds Australasia will update the definition of a Prohibited Substance within Greyhounds Australasia Rule 1. The aim of this change is to provide a more detailed list of prohibited substance categories while also aligning the definition with other racing codes, which is important for cross-code regulatory bodies and the laboratories.

Although the changes appear detailed, participants should be reassured that the change in definition will not significantly change the way laboratories conduct testing or report the detection of prohibited substances. The definition of prohibited substance is largely unchanged in practice but is hopefully much easier for participants to understand and ensure they present their greyhounds free of prohibited substances on race day.

The revised definition of 'prohibited substance' within GAR 1 is as follows:

"prohibited substance" means a substance defined by the following criteria or which falls within any of the groups of substances declared herein unless it is an exempted substance.

(a) Substances capable at any time of causing either directly or indirectly an action or effect, or both an action and effect, within one or more of the following mammalian body systems:

i. the nervous system
ii. the cardiovascular system
iii. the respiratory system
iv. the digestive system
v. the musculo-skeletal system
vi. the endocrine system
vii. the urinary system
viii. the reproductive system
ix. the blood system
x. the immune system

(b) Substances falling within, but not limited to, the following categories:

i. acidifying agents
ii. adrenergic blocking agents
iii. adrenergic stimulants
iv. agents affecting calcium and bone metabolism
v. agents that directly or indirectly affect or manipulate gene expression
vi. alcohols
vii. alcalinising agents
viii. anabolic agents
ix. anaesthetic agents
x. analgesics
xi. antiangina agents
xii. antianxiety agents
xiii. antiarrhythmic agents
xiv. anticholinergic agents
xv. anticoagulants
xvi. anticonvulsants
xvii. antidepressants
xviii. antiepileptic agents
xix. antifibrinolytic agents
xx. antihistamines
xxi. antihypertensive agents
xxii. anti-inflammatory agents
xxiii. antinauseants
xxiv. antineoplastic agents
xxv. antipsychotic agents
xxvi. antipyretics
xxvii. antirheumatic agents
xxviii. antispasmodic agents
xxix. antithrombotic agents
xxx. antitussive agents
xxxi. blood coagulants
xxxii. bronchodilators
xxxiii. bronchospasm relaxants
xxxiv. buffering agents
xxxv. central nervous system stimulants
xxxvi. cholinergic agents
xxxvii. corticosteroids
xxxviii. depressants
xxxix. diuretics
xl. erectile dysfunction agents
xli. fibrinolytic agents
xlii. haematopoietic agents
xliii. haemostatic agents
xliv. hormones (including trophic hormones) and their synthetic counterparts
xlv. hypnotics
xlvi. hypoglycaemic agents
xlvii. hypolipidaemic agents
xlviii. immunomodifiers
xlix. masking agents
l. muscle relaxants
li. narcotic analgesics
lii. neuromuscular agents
liii. oxygen carriers
liv. plasma volume expanders
lv. respiratory stimulants
lvi. sedatives
lvii. stimulants
lviii. sympathomimetic amines
lix. tranquillisers
lx. vasodilators
lxi. vasopressor agents
lxii. vitamins administered by injection

(c) any substance administered to disguise or make undetectable, or attempt to disguise or make undetectable, the administration of any of the substance(s) referred to in paragraph (a) or (b);

(d) any substance(s) specified in Schedules 1 to 9 inclusive of the Standard for the Uniform Scheduling of Medicines and Poisons (Commonwealth) as amended from time to time.

(e) unusual or abnormal amounts of an endogenous, environmental, dietary, or otherwise naturally present, substance;

(f) a metabolite, isomer or artefact of any of the substance(s) referred to in paragraphs (a), (b), (c) or (d) irrespective of whether or not such metabolite, isomer or artefact has any pharmacological effect;

In addition to the definition above, various thresholds exist for prohibited substances that occur naturally within a greyhound and are listed within GAR 83 (6) – (12). These thresholds include testosterone, ethanol metabolites, hydrocortisone, 3-methoxytyramine, cobalt and arsenic.

Permanently banned prohibited substances are a type of prohibited substance listed within GAR 79A which are banned at all times and tested for in out of competition testing as well as standard race day swabbing. These substances must never be possessed, acquired, attempted to be acquired, administered or allowed to be administered to any greyhound from birth until retirement.

Prohibited substances can be possessed providing that is done so in accordance with GAR 84 and can be administered where reasonably indicated, but must not be detected in a sample taken when presented for an Event. Any use must be recorded in treatment records (GAR 84A).

Substances specified in Schedules 1 to 9 of the Standard are regularly updated by the federal Government and can be viewed here: https://www.tga.gov.au/publication/poisons-standard

Table 1 below gives examples of specific prohibited substances that fall into each category listed within part b of the definition, but this list is not exhaustive and for clarification, participants should check with their veterinarian or controlling body before administering.
Table 1: Examples of prohibited substances described in Part b of the definition of prohibited substance (N.B. Some examples given also fall within GAR 79A and are permanently banned prohibited substances. Again, participants should check with their veterinarian or controlling body before administering.)

<table>
<thead>
<tr>
<th>Prohibited Substance Part B</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acidifying agents</td>
<td>Ammonium chloride</td>
</tr>
<tr>
<td>Adrenergic blocking agents</td>
<td>Cyproterone, Metoprolol</td>
</tr>
<tr>
<td>Adrenergic stimulants</td>
<td>Adrenaline, Isoprenaline</td>
</tr>
<tr>
<td>Agents affecting calcium and bone metabolism</td>
<td>Calcitriol, Growth Hormone</td>
</tr>
<tr>
<td>Agents that directly or indirectly affect or manipulate gene expression</td>
<td>Insulin Like Growth Factor 1, Darbepoetin alfa</td>
</tr>
<tr>
<td>Alcohols</td>
<td>Alcohol, Methanol</td>
</tr>
<tr>
<td>Alkalising agents</td>
<td>Sodium bicarbonate</td>
</tr>
<tr>
<td>Anabolic agents</td>
<td>Testosterone, Stanazolol, Methandriol, Nandrolone, Ethyloestrenol (males)</td>
</tr>
<tr>
<td>Anaesthetic agents</td>
<td>Lignocaine, Bupivacaine, Procaine, Ketamine</td>
</tr>
<tr>
<td>Analgesics</td>
<td>Tramadol, Dipyrone (Metamizole)</td>
</tr>
<tr>
<td>Anti-angina agents</td>
<td>Amlodipine, Glyceryl trinitrate</td>
</tr>
<tr>
<td>Anti-anxiety agents</td>
<td>Diazepam, Alprazolam</td>
</tr>
<tr>
<td>Anti-arrhythmic agents</td>
<td>Atenolol, Sotalol, Lignocaine, Disopyramide</td>
</tr>
<tr>
<td>Anticholinergic agents</td>
<td>Dextromethorphan, Bupropion</td>
</tr>
<tr>
<td>Anti-coagulants</td>
<td>Heparin sodium, Rivaroxaban</td>
</tr>
<tr>
<td>Anti-convulsants</td>
<td>Clonazepam, Gabapentin</td>
</tr>
<tr>
<td>Anti-depressants</td>
<td>Clomipramine, Fluoxetine, Venlafaxine</td>
</tr>
<tr>
<td>Anti-emetics</td>
<td>Metoclopramide, Maropitant</td>
</tr>
<tr>
<td>Anti-fibrinolytic agents</td>
<td>Aminocaproic acid, Tranexamic acid</td>
</tr>
<tr>
<td>Anti-histamines</td>
<td>Chlorphenamine, Fexofenadine</td>
</tr>
<tr>
<td>Anti-hypertensive agents</td>
<td>Quinapril, Spironolactone</td>
</tr>
<tr>
<td>Anti-inflammatory agents</td>
<td>Carprofen, Meloxicam, Tolfenamic acid, Diclofenac, Flunixin, Ketoprofen, Piroxicam, Firocoxib, Phenylbutazone, Corticosteroids</td>
</tr>
<tr>
<td>Anti-nauseants</td>
<td>Mirtazapine, Prochlorperazine</td>
</tr>
<tr>
<td>Anti-neoplastic agents</td>
<td>Letrozole, Medroxyprogesterone acetate</td>
</tr>
<tr>
<td>Anti-psychotic agents</td>
<td>Lithium carbonate, Risperidone</td>
</tr>
<tr>
<td>Anti-pyretics</td>
<td>Ketoprofen, Salicylates</td>
</tr>
<tr>
<td>Anti-rheumatoid agents</td>
<td>Sodium aurothiomalate, Methotrexate</td>
</tr>
<tr>
<td>Anti-spasmodic agents</td>
<td>Hyoscine, Propantheline</td>
</tr>
<tr>
<td>Anti-thrombotic agents</td>
<td>Prasugrel, Ticlopidine</td>
</tr>
<tr>
<td>Anti-tussive agents</td>
<td>Pholcodine, Acetylcysteine, Guaifenesin, Dextromethorphan</td>
</tr>
<tr>
<td>Blood coagulants</td>
<td>Aprotinin, Tranexamic acid</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>Salbutamol, Clenbuterol</td>
</tr>
<tr>
<td>Bronchospasm relaxants</td>
<td>Theophylline, Terbutaline</td>
</tr>
<tr>
<td>Buffering agents</td>
<td>Beta-alanine, Sodium bicarbonate</td>
</tr>
<tr>
<td>Central nervous system stimulants</td>
<td>Cocaine, Amphetamine, Methamphetamine, Cafféine, Theobromine, Benzylpiperazine</td>
</tr>
<tr>
<td>Cholinergic agents</td>
<td>Physostigmine, Pilocarpine</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Dexamethasone, Methylprednisolone, Fludrocortisone, Prednisolone, Hydrocortisone</td>
</tr>
<tr>
<td>Depressants</td>
<td>Pentobarbitone, Alcohol, Cannabis, Arsenic</td>
</tr>
<tr>
<td>Classification</td>
<td>Examples</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Diuretics</td>
<td>Frusemide, Hydrochlorothiazide, Spironolactone</td>
</tr>
<tr>
<td>Erectile dysfunction agents</td>
<td>Sildenafil citrate, Tadalafil</td>
</tr>
<tr>
<td>Fibrinolytic agents</td>
<td>Streptokinase, Tissue plasminogen activator</td>
</tr>
<tr>
<td>Haematopoietic agents</td>
<td>Cobalt, Cyanocobalamin, Ferumoxytol</td>
</tr>
<tr>
<td>Haemostatic agents</td>
<td>Aminocaproic acid, Tranexamic acid</td>
</tr>
<tr>
<td>Hormones (including trophic hormones)</td>
<td>Nandrolone, Testosterone, Boldenone</td>
</tr>
<tr>
<td>and their synthetic counterparts</td>
<td></td>
</tr>
<tr>
<td>Hypnotics</td>
<td>Zolpidem, Mirtazapine</td>
</tr>
<tr>
<td>Hypoglycaemic agents</td>
<td>Metformin, Acarbose</td>
</tr>
<tr>
<td>Hypolipidaemic agents</td>
<td>Atorvastatin, Fenofibrate</td>
</tr>
<tr>
<td>Immunomodifiers</td>
<td>Peginterferon Alfa 2A/2B, Plerixafor, Cimetidine</td>
</tr>
<tr>
<td>Masking agents</td>
<td>Diuretics</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>Dantrolene sodium, Diazepam</td>
</tr>
<tr>
<td>Narcotic analgesics</td>
<td>Morphine, Buprenorphine, Fentanyl, Oxycodone, Dermorphins</td>
</tr>
<tr>
<td>Neuromuscular agents</td>
<td>Succinylcholine, Doxacurium</td>
</tr>
<tr>
<td>Oxygen carriers</td>
<td>Perfluorochemicals, and Modified Hemoglobin Products</td>
</tr>
<tr>
<td>Plasma volume expanders</td>
<td>Polygeline, Hetastarch</td>
</tr>
<tr>
<td>Respiratory stimulants</td>
<td>Doxapram</td>
</tr>
<tr>
<td>Sedatives</td>
<td>Xylazine, Phenobarbitone, Acepromazine</td>
</tr>
<tr>
<td>Stimulants</td>
<td>Caffeine, Dexamphetamine, Modafinil, Methylphenidate, Pseudoephedrine</td>
</tr>
<tr>
<td>Sympathomimetic amines</td>
<td>Methylphenidate, Pseudoephedrine</td>
</tr>
<tr>
<td>Tranquillisers</td>
<td>Acepromazine, Zolazepam</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>Heptaminol, Clenbuterol, Salbutamol, Minoxidil</td>
</tr>
<tr>
<td>Vasopressor agents</td>
<td>Dobutamine, Phenylephrine</td>
</tr>
<tr>
<td>Vitamins administered by injection</td>
<td>Vitamin B12 (Cyanocobalamin), Vitamin C (Ascorbic acid), Vitamin B-Complex</td>
</tr>
</tbody>
</table>

* Some substances listed are permanently banned prohibited substances
Norethisterone for the control of oestrus in females to be introduced as an exempted substance into the Greyhounds Australasia Rules

Notice to trainers – Norethisterone usage in greyhounds

On 1 March 2018, Greyhounds Australasia will introduce norethisterone to the list of Exempted Substances within GAR 1 Definitions as follows:

“Ethyoestrenol or norethisterone when administered orally to a female greyhound and where it has been prescribed by a veterinary surgeon for the sole purpose of regulating or preventing oestrus in that female greyhound.”

Female greyhounds are unable to race whilst in season, which can occur up to twice a year and reduce their available racing career. Since the introduction of a ban on previously used anabolic androgenic steroids (AAS), oestrus control has been limited to the use of ethyoestrenol. Following a review, including research with The University of Nottingham and the Greyhound Board of Great Britain where norethisterone is used successfully, Greyhounds Australasia has agreed to allow norethisterone as an alternative non-AAS means of postponing oestrus in females.

Participants are encouraged to discuss with their veterinarian the options available for regulating or preventing oestrus in their greyhounds in order to make an informed decision. Options available include no treatment (allow natural cycling), spaying (permanent surgical option), or medication with ethyoestrenol or norethisterone.

Norethisterone is a synthetic form of progesterone and belongs to a class of drugs known as progestins, and is commonly used in human contraceptive pills. Progestins prevent oestrus by inhibiting the hormone that causes ovulation i.e. they act on the pituitary gland to reduce its responsiveness to gonadotrophin releasing hormone (GnRH) and blocking the effect of oestradiol on GnRH receptor expression. This leads to a suppression of reproductive cyclicity and prevents oestrus.

From a survey of UK trainers, norethisterone effectively and temporarily postpones oestrus in most females, but some side effects were reported including frequent urination, clitoral enlargement or a behaviour change. A separate review of performance data found that
greyhounds performed up to one length slower if treated with norethisterone. These are similar to those side effects reported when using ethyloestrenol and were less likely at decreased doses (2.5mg/day compared to 5mg/day). The performance decrease found is similar to that seen when progesterone is naturally elevated during a normal oestrus cycle.

There are two products that are registered with the Therapeutic Goods Administration (TGA) that contain only norethisterone - Primolut N™ and Noriday 28 Day™. Given the low dose contained in the latter product, Primolut N is likely to be an easier and more economic method of controlling oestrus for trainers. The cost per day of ½ - 1 tablet once daily of Primolut N is similar to ethyloestrenol at 45 - 90 cents.

Many products contain norethisterone in combination with other substances (e.g. ethinylestradiol - *an oestrogen not to be confused with ethyloestrenol*) - these additional substances are not exempted from being a prohibited substance and can cause a positive swab. Trainers administering these combination products do so at their own risk.

There are no longer any Australian Pesticides and Veterinary Medicines Authority (APVMA) registered products containing ethyloestrenol available in Australia. There is however one product containing ethyloestrenol (Orabolin) which has been produced under APVMA permit for several years. Until a fully registered product returns to the market, the reliable ongoing supply of ethyloestrenol may be at risk.

Like ethyloestrenol, norethisterone must only be used for the purposes of regulating or preventing oestrus and can only be prescribed by a registered Veterinary Surgeon to an animal under his or her care after establishing a therapeutic need for that substance. That veterinary surgeon would be prescribing the product ‘off-label’ as neither substance is registered for the control of oestrus in canines. The product must be labelled in accordance with regulatory legalisation.

As both exempted substances are a Schedule 4 (Prescription Only) substance, trainers are reminded of their obligations under GAR 83A Raceday Treatment (i.e. do not administer on the day of an event until home after racing) and under GAR 84A Treatment Records (i.e. record administrations to each greyhound in their treatment book).

For further information please contact your state controlling body.
Local Rule to prevent Greyhounds competing on consecutive days to be extended into Greyhounds Australasia Rules

Notice to trainers – National ban on consecutive days racing

On 1 March 2018, Greyhounds Australasia will introduce GAR 21A, prohibiting a greyhound from competing in an Event on two consecutive days as follows:

“A greyhound shall not be eligible to compete in more than one (1) Event over any consecutive two (2) day period, except that a greyhound may be permitted to compete in more than one (1) Event at a coursing meeting.”

Similar existing Local Rules have already been introduced and enforced by controlling bodies including Western Australia, Tasmania, South Australia and Victoria. This rule addition further harmonises the national rules and gives clarity by establishing a national standard.

While unlikely to effect the vast majority of trainers and their nominations, this new rule aims to safeguard the health and welfare of racing greyhounds by ensuring increased rest and recovery time between competition allowing them a better chance at performing at their best and remaining in good health. Greyhounds that are not allowed adequate rest periods between races are generally at increased risk of metabolic conditions and musculoskeletal injuries.

For further information please contact your state controlling body.
Notice to trainers – Expansion of permanently banned prohibited substance list within GAR79A Out of Competition Testing

On 1 March 2018, Greyhounds Australasia will expand the list of Permanently Banned Prohibited Substances tested for in out of competition testing. Participants are advised that in accordance with GAR 79A they must never possess, acquire, attempt to acquire, administer or allow to be administered to any greyhound from birth until retirement, any substance included within this list.

Compliance with these rules will be enforced by state controlling bodies through all available means including regular kennel inspections, inspections of medications and treatment records, working with other regulatory bodies, and regular out of competition testing, as well as through routine race day sampling. Controlling bodies may conduct out of competition testing on any greyhound at any time, regardless of whether it is named, nominated or not and may take samples of any type listed within GAR 80.

As per GAR 79A (3) any greyhound that tests positive to any permanently banned prohibited substance shall be withdrawn from any Event in which it is nominated to compete and will be ineligible to be nominated for any further Event until a sample is subsequently taken that does not contain any of the substances specified in GAR 79A (2).

The amended list within GAR 79A (2) is as follows:

“(2) The following substances are deemed to be Permanently Banned Prohibited Substances and shall include a metabolite, isomer or artefact of any of the substances specified within.”

(i) Erythropoiesis-stimulating agents, including but not limited to erythropoietin (EPO), epoetin alfa, epoetin beta, epoetin delta, epoetin omega, novel erythropoiesis stimulating protein (NESP; darbepeoietin alfa), and methoxy polyethylene glycol-epoetin beta (Mircera) and other continuous erythropoietin receptor activators.

(ii) Gonadotropins, including luteinising hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG) and equine chorionic gonadotropin (eCG; pregnant mare serum gonadotropin; PMSG).

(iii) Gonadotropin releasing hormone (GnRH; gonadorelin).
(iv) Corticotropins, including adrenocorticotropic hormone (ACTH) and tetracosactrin (tetracosactide).

(v) Substances listed in Schedule 8 and Schedule 9 of the Standard for the Uniform Scheduling of Medicines and Poisons contained in the Australian Poisons Standard, as amended from time to time.

(vi) Diacetylmorphine (heroin), benzoylmethylecgonine (cocaine), cannabinoids and lysergic acid diethylamide (LSD), gamma-hydroxybutyric acid (GHB) and its salts and amphetamines including amphetamine, methamphetamine and methylenedioxymethamphetamine (MDMA).

(vii) Insulins and insulin-like growth factor-1.

(viii) Growth hormones and their releasing factors.

(ix) Selective receptor modulators including but not limited to selective androgen receptor modulators (SARMs), selective estrogen receptor modulators (SERMS), selective opiate receptor modulators (SORMS) and selective glucocorticoid receptor agonists.

(x) Peroxisome proliferator activated receptor δ (PPARδ) agonists, including but not limited to GW 1516.

(xi) AMPK activators, including but not limited to AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide).

(xii) Other agents that directly or indirectly affect or manipulate gene expression.

(xiii) Hypoxia inducible factor (HIF) stabilisers, including but not limited to cobalt and FG-4592, and hypoxia inducible factor (HIF) activators, including but not limited to argon and xenon.

(xiv) Agents modifying myostatin function, including but not limited to myostatin inhibitors.

(xv) Oxygen carriers including but not limited to perfluorochemicals, faproxiral and modified haemoglobin products.

(xvi) Thymosin beta.

(xvii) Venoms of any species or derivatives thereof.

(xviii) Synthetic proteins and peptides and synthetic analogues of endogenous proteins and peptides not registered for medical or veterinary use in Australia or New Zealand.

(xix) Any substance capable of disguising or making undetectable the administration or presence of any Permanently Banned Prohibited Substance.

(xx) Anabolic androgenic steroids excluding those that are defined as an exempted substance pursuant to GARI.

(xxi) Non-erythropoietic EPO-receptor agonists.
Allosteric effectors of haemoglobin, including but not limited to ITPP (myo-inositol trispyrophosphate).

Haematopoietic growth factors, including but not limited to filgrastim.

Hydrocortisone (excluding registered topical preparations when administered topically).

Description of permanently banned prohibited substances

A number of the substances within this list have been banned due to concerns regarding their integrity and/or animal welfare risks. They have the capability of affecting the behavior, condition or performance of a greyhound. Participants are advised that in accordance with GAR 79A they must never possess, acquire, attempt to acquire, administer or allow to be administered to any greyhound from birth until retirement, any substance included within this list.

(i) Erythropoiesis-stimulating agents can increase red blood cell production and prolong their life in circulation. This leads to an increased concentration of red blood cells in the racing greyhound, which leads to increased oxygen transporting capacity and reduces the effects of fatigue on the muscles. This can increase performance in the racing greyhound. These substances all have serious welfare concerns in the racing greyhounds as they have been linked to cardiac arrest, infarctions of vital organs and cerebral hemorrhage.

(ii) Gonadotropins (e.g. Chorulon) if administered will increase testosterone levels and may breach the 5β-androstane-3α, 17β-diol (βαβ) thresholds regardless of whether testing is conducted in or out competition. Use in dogs may increase muscle mass, increase endurance and alter their behavior (aggression and chasing desire).

(iii) Gonadotropin releasing hormones (e.g. Fertagyl, Receptal, Ovuplant, Suprelorin) if administered will increase testosterone levels and may breach the 5β-androstane-3α, 17β-diol (βαβ) thresholds regardless of whether testing is conducted in or out competition. Use in dogs may increase muscle mass, increase endurance and alter their behavior (aggression and chasing desire).

(iv) Corticotropins (e.g. Synacthen) if administered will increase the levels of naturally produced glucocorticoids which have anti-inflammatory and pain-relieving properties. Use during competition could inhibit sensation of muscle or joint pain and increase the fatigue threshold.

(v) Substances listed in Schedule 8 and Schedule 9 of the Standard for the Uniform Scheduling of Medicines and Poisons contained in the Australian Poisons Standard are defined by the Australian Government as Controlled Drugs and Prohibited Substances and is regularly updated and the latest version can be viewed at https://www.tga.gov.au/publication/poisons-standard-susmp. These substances may have a performance enhancing or decreasing effect in the racing greyhound and provide serious welfare concerns through administration of these substances. Possession of these substances is illegal without appropriate authority.
Diacetylmorphine (heroin), benzoylecgonine (coca), cannabinoids and  
lysergic acid diethylamide (LSD), gammahydroxybutyric acid (GHB) and its salts  
and amphetamines including amphetamine, methylamphetamine and  
methylenedioxymethamphetamine (MDMA) are all illicit substances  
and possession is illegal. These substances may have a performance enhancing or  
decreasing effect in the racing greyhound and provide serious welfare concerns  
through administration of these substances.

Insulins and insulin-like growth factor-1 can affect metabolism, growth and  
development of the racing greyhound. They can produce a performance enhancing  
effect, and have welfare concerns for greyhounds which are treated with these  
substances without therapeutic cause, however treatment for therapeutic reasons  
would require retirement of the greyhound from racing.

Growth hormones and their releasing factors have the ability to increase  
musculoskeletal growth and development in the racing greyhound and can have a  
performance enhancing effect in addition to the potential welfare concerns.

Selective receptor modulators including but not limited to selective androgen  
receptor modulators (SARMS), selective estrogen receptor modulators (SERMS),  
selective opiate receptor modulators (SORMS) and selective glucocorticoid receptor  
agonists have the ability to have anabolic, behavioral, anti-inflammatory, analgesic  
or performance effects by switching on normal endogenous production pathways.

Peroxisome proliferator activated receptor δ (PPARδ) agonists, including but not  
limited to GW 1516 have the ability to mimic the beneficial effects of exercise on  
muscle and metabolic systems and can have a performance enhancing effect.

AMPK activators, including but not limited to AICAR (5-amino-1-β-D-  
d-ribofuranosyl-imidazole-4-carboxamide have been shown to increase exercise  
speed and endurance in sedentary mice and thus its administration in racing  
greyhounds may increase performance.

Other agents that directly or indirectly affect or manipulate gene expression if  
administered would be considered gene doping. These substances may alter  
metabolic systems which can lead to increased performance and also present serious  
wellfare risks for greyhounds.

Hypoxia inducible factor (HIF)-1 stabilisers, including cobalt and FG-4592, and  
HIF activators, including xenon and argon, can increase red blood cell production  
and prolong their life in circulation. Increased concentration of red blood cells leads  
to increased oxygen transporting capacity and reduces the effects of fatigue on the  
muscles. In addition to the potential for increased performance these substances can  
have serious welfare concerns in the racing greyhound as they chemically mimic  
the effects of hypoxia (low oxygen). Possession or administration of registered,  
appropriately obtained and labelled products containing cobalt and vitamin B12 is  
allowed under this rule where appropriate, but the cobalt threshold will be enforced  
on race day (GAR 10). Possession of highly concentrated cobalt salts is likely to be  
considered a breach of GAR 79A(7).
(xiv) Agents modifying myostatin function, including myostatin inhibitors can increase muscle mass and endurance which can lead to a performance enhancing effect.

(xv) Oxygen carriers including but not limited to perfluorochemicals, efaproxiral and modified hemoglobin products increase the amount of oxygen in circulation which can then feed muscles and other metabolic systems which are stressed during racing thereby reducing fatigue. They also represent welfare concerns if administered to greyhounds.

(xvi) Thymosin beta is a peptide which is capable of regulating cell migration and is able to promote blood vessel development and tissue repair after injury. It has an anti-inflammatory action by down regulation of cytokines and can promote the maturation of stem cells, healing damaged muscles. Due to these effects it would be considered a performance enhancing substance.

(xvii) Venoms of any species or derivatives thereof have a wide and varied effect on animals which are all detrimental. These effects range from neurotoxic, myotoxic and hemotoxic and can cause severe illness and death in the greyhound. Although rumoured to improve performance, they would all have a decrease performance and raise serious welfare issues if administered to a greyhound.

(xviii) Synthetic proteins and peptides and synthetic analogues of endogenous proteins and peptides not registered for medical or veterinary use in Australia or New Zealand are all banned and can have a range of effects such as increasing muscle mass and efficiency of metabolism under exercise conditions. These substances would generally have a positive effect on condition and performance.

(xix) Any substance capable of disguising or making undetectable the administration or presence of any Permanently Banned Prohibited Substance i.e. masking agents. Although few are known to exist, due to their mode of action and their potential effect on the health of greyhounds, they present serious welfare and integrity concerns and so their use is banned.

(xx) Anabolic androgenic steroids excluding ethyloestrenol for controlling oestrus in the female are banned. Use in greyhounds leads to an unfair performance advantage through increasing muscle mass, increasing endurance and altering behavior (aggression and chasing desire). They can also cause several negative health effects in the greyhound and raise potential welfare implications if administered.

(xxii) Non-erythropoietic EPO-receptor agonists are a group of substances that can increase red blood cell production and prolong their life in circulation. This leads to an increased concentration of red blood cells in the racing greyhound, which leads to increased oxygen transporting capacity and reduces the effects of fatigue on the muscles. This can increase performance in the racing greyhound. These substances all have serious welfare concerns in the racing greyhounds as they have been linked to cardiac arrest, infarctions of vital organs and cerebral hemorrhage.

(xxii) Haematopoietic growth factors, including but not limited to filgrastim have no therapeutic indication in the greyhound and their administration can alter the
synthesis of red and white blood cells. Administration in the greyhound raises serious welfare concerns due to their side effects and potential integrity risks.

(xxiii) Hydrocortisone is a substance that produces pain-relieving, anti-inflammatory effects and can also alter metabolism and increase the fatigue threshold which is likely to lead to performance enhancement in the racing greyhound. APVMA or TGA registered topical products can be prescribed by your veterinarian after having established a therapeutic need for that product and can only be administered topically (i.e. on the skin, in the ear). The hydrocortisone threshold (GAR 83 (8)) will now be enforced both on race day and out of competition, and administration of hydrocortisone (e.g. Hysone, Solu-Cortef) will lead to a breach of the threshold. Where systemic corticosteroids are required for treatment, veterinarians can continue to prescribe veterinary products that contain other corticosteroids (e.g. prednisolone, dexamethasone, etc)

For further information please contact your controlling body.
Change to Rule 83 in Greyhounds Australasia Rules:
Greyhound to be free of prohibited substances

Notice to trainers – Renumbering of GAR 83

On 1 March 2018, Greyhounds Australasia will insert an amended Rule 83(4) into the Greyhounds Australasia Rules. The aim of this change is to reflect the renumbering previously undertaken in this Rule. There are no substantive changes arising from the renumbering.

The updated Rule 83(4) reads:

*A greyhound presented for an event contrary to sub-rules (1), (1A), or (2) shall be disqualified from the event or any benefit from a trial or test.*

The effect of this amendment is to ensure that Rule 83(4) captures the correct provisions in 83(1), 83(1A), and 83(2).
Enhanced Restrictions on Treatment prior to racing to be introduced into the Greyhounds Australasia Rules

Notice to trainers – GAR 83A Raceday Treatment rule extended to prohibit the administration of an injectable substance for a further one clear day prior to racing.

An essential principle of greyhound racing is that greyhounds are to compete free of prohibited substances to ensure a level playing field for all participants and protect animal welfare.

To assist this, on 1 March 2018, Greyhounds Australasia will introduce further restrictions regarding treatment of greyhounds in the period prior to racing within GAR 83A as follows:

“(1) No person without the permission of the Stewards may administer or cause to be administered any treatment to a greyhound at any time on the day of the meeting until that greyhound is no longer presented for an Event.

(2) The Stewards may order that any greyhound that has been administered a treatment in contravention of sub-rule (1) of this Rule be withdrawn from an Event.

(3) In addition to sub-rule (1) of this Rule, no person without the permission of Stewards may administer or cause to be administered any injectable substance to a greyhound at any time on the day prior to the day of an Event that it is nominated to compete in.

For the purposes of this Rule, “treatment” includes:

a) All Controlled Drugs (Schedule 8) administered by a veterinarian;

b) All Prescription Animal Remedies and Prescription Only Medicines (Schedule 4);

c) Any injectable substance not already specified in this Rule;

(3) In addition to sub-rule (1) of this Rule, no person without the permission of Stewards may administer or cause to be administered any injectable substance to a greyhound at any time on the day prior to the day of an Event that it is nominated to compete in.

For the purposes of this Rule, “treatment” includes:

a) All Controlled Drugs (Schedule 8) administered by a veterinarian;

b) All Prescription Animal Remedies and Prescription Only Medicines (Schedule 4);

c) Any injectable substance not already specified in this Rule;

d) All Pharmacist Only (Schedule 3) and Pharmacy Only (Schedule 2) medicines;

e) All veterinary and other substances containing other scheduled and unscheduled prohibited substances.”

For the purposes of this Rule, “day” means the 24 hour period from 12:01am to 12 midnight on any calendar day.
Therefore, the change now means that no injectable substance can be administered to a greyhound on the day prior to an Event it is nominated to compete in. As is currently the case, an injectable substance is any substance that is designed to be, or capable of being, administered by injection regardless of whether it is given by injection.

The remainder of the rule remains the same and no “treatment” can be given to a greyhound on the day the greyhound is nominated to compete in an Event i.e. no ‘treatment’ on the calendar day from 12:01am until it is removed from the racecourse after the completion of that Event with the permission of the Stewards pursuant to Rule 42(2) or is scratched with the permission of the Stewards.

Importantly no injectables, controlled drugs (S8), prescription medicines (S4), pharmacist only (S3) or pharmacy only (S2) medicines, or other prohibited substances should be given to greyhounds on race day under any circumstances.

This rule change brings regulations on the treatment of greyhounds close to racing more in line with those in the thoroughbred and harness racing codes and further ensures a level playing field for all participants. It aims to reduce the use of injections in the greyhound racing industry, thereby enhancing animal welfare and reducing the proportion of positive swabs.

There is no peer-reviewed scientific evidence published that proves the use of supplement injections in the pre-race period leads to improved performance or recovery in greyhounds. However, there are concerns that the trauma caused by injections can have negative welfare implications and may reduce performance, while significantly enhancing the risk of returning a positive swab.

By heightening restrictions on treatments close to racing it is hoped that those participants who still consider injections and other treatments are necessary for success can move forward and help advance a sustainable industry that puts the greyhound’s welfare first and above all other considerations.

Where a “treatment” is required to be given daily e.g. oestrous suppression, this can be given after the greyhound has completed its engagement in an Event and left the racecourse (i.e. given on the nightly feed at home).

The officiating Veterinary Surgeon has the permission of Stewards to treat greyhounds on the racecourse as required in conducting their official duties.

Only normal feeding and supplementation that can be achieved by the greyhound voluntarily eating or drinking can be considered acceptable on the day of racing. For the avoidance of doubt, in order to comply with this rule no tablets, capsules, caplets, pills, etc or any liquid, paste, etc that requires syringing into the oral cavity to encourage administration should be administered on the day of racing. Standard administration of an oral electrolyte supplement is acceptable if voluntarily drunk or eaten by the greyhound.

For further information please contact your state controlling body.
Amendments to be made to Treatment Record requirements in Greyhounds Australasia Rules

Notice to trainers – Amendment to GAR 84A Treatment records to be kept, clarifying need for the person in charge of a greyhound to make records on the day of the treatment.

On 1 March 2018, Greyhounds Australasia will introduce a change to GAR 84A (2) Treatment records to be kept as follows:

(1) The person in charge of a greyhound must keep and retain records detailing all vaccinations, antiparasitics and medical treatments administered to a greyhound from the time the greyhound enters their care until the greyhound leaves their care and for a minimum of two (2) years. Such record of treatment must be produced for inspection when requested by a Steward or a person authorised by the Controlling Body. Any person responsible for a greyhound at the relevant time who fails to comply with any provision of this rule shall be guilty of an offence.

(2) Each record of treatment kept in accordance with this rule must be made by midnight on the day on which the treatment was given and, as a minimum requirement, include the following information:

   a) Name of the greyhound;
   b) Date and time of administration of the treatment;
   c) Name of the treatment (brand name or active constituent);
   d) Route of administration;
   e) Amount given;
   f) Name and signature of person or persons administering and/or authorising treatment.

For the purposes of sub-rule (2) “day” means the 24 hour period from 12:01am to 12 midnight on any calendar day.

(3) For the purposes of this rule “treatment” includes:

   a) All Controlled Drugs (Schedule 8) administered by a veterinarian;
   b) All Prescription Animal Remedies and Prescription Only Medicines (Schedule 4);
   c) Any injectable substance not already specified in this Rule;
   d) All Pharmacist Only (Schedule 3) and Pharmacy Only (Schedule 2) medicines;
   e) All veterinary and other substances containing other scheduled and unscheduled prohibited substances.

Participants are advised that these are the minimum requirements required under the Greyhounds Australasia Rules, and additional recording obligations may be required under
various Codes of Practice (CoP) operating in each state or territory. As per the introduction of this rule in 2014, participants are encouraged to record all treatments administered to greyhounds under their care, however unless a CoP requires otherwise, participants need only keep a record of treatment for greyhounds over the age of 16 months until it is retired from racing. A registered person must keep this record for a minimum of two years after either retirement of the greyhound or the greyhound leaving the care of that person.

Participants are encouraged to familiarize themselves with this rule and the amendments to ensure that their treatment records are compliant. The amendments now require participants to record the time as well as the date that the treatment was administered, and must make that record by midnight on the day of the treatment.

Greyhounds Australasia has implemented these minor rule changes to better align with other Australian racing codes and to address some concerns raised during Stewards inquiries. The amendments give further clarity for participants and controlling bodies are hopeful there will be a reduction in non-compliance with this rule now that the requirements are clearer.

Compliance with these rules will be enforced by state controlling bodies through all available means, including regular kennel inspections that will include inspection of medications and treatment records. Trainers who do not comply with the amendments of GAR 84A may find themselves subject to disciplinary proceedings by their controlling body.

For further information please contact your controlling body.